The ORION Trial

Background

Haemorrhoids are common, affecting as many as 1 in 3 of the population, and can cause symptoms including discomfort and bleeding, and are a common reason for review in a surgical clinic. Over 20,000 operations are carried out each year in England alone. Repeated visits to health care services as well as prolonged recovery after some interventions represents a significant disruption to the personal and working lives of a large proportion of the population. 

Interventions, for those whose symptoms remain after trying conservative management in the form of diet and habit modification, are influenced mainly by the degree of prolapse. These interventions range from rubber band ligation (RBL), which appears safe, and is easy to carry out, to haemorrhoidal artery ligation, stapled haemorrhoidopexy or haemorrhoidectomy. All interventions are available on the NHS. 

An alternative procedure to treat haemorrhoids is the use of radiofrequency ablation (RFA). RFA is primarily intended for use in patients whose haemorrhoid has failed to respond to less invasive outpatient procedures such as RBL as well as an alternative to operative procedures for those with a higher degree of prolapse where office procedures are likely to be ineffective. RFA is available to the NHS through the Rafaelo® device and has many potential advantages over the other surgical interventions and is therefore increasing in popularity. As the intervention does not excise tissue or generate excessive heat it should result in minimal discomfort and has been suggested to be faster than excisional treatments with a more rapid recovery. The evidence base for these claims is however limited, mainly from small cohort studies in specialist settings. More importantly, the promising longer-term efficacy has not been subject to a randomised comparison.

---

The ORION trial

RFA has not been tested enough for us to be sure it is as good as some suggest, and the cost is higher than that of other interventions. The aim of the ORION trial is to assess whether RFA is as efficacious as existing methods of treating haemorrhoids and if it is also superior in terms of pain and recurrence. 

ORION will be a full-scale trial that compares RFA’s effectiveness with the surgeon’s choice of surgery for patients whose haemorrhoids are severe enough to warrant surgery. The control arm of the trial will be the surgeon’s choice of any of the three most used surgeries – haemorrhoidal artery ligation, stapled haemorrhoidopexy or haemorrhoidectomy – and the intervention arm will be surgery using RFA. Patients will be randomised to either arm. 

View the ORION trial website

---

Central study staff

Name	Title	Organisation	Email
Steven Brown	Chief Investigator	Sheffield Teaching Hospitals NHS Foundation Trust	steven.brown13@nhs.net
Daniel Hind	Trial Oversight	University of Sheffield	d.hind@sheffield.ac.uk
Carla Girling	Study Manager	University of Sheffield	c.girling@sheffield.ac.uk
Annie Little	Trials Support Officer	University of Sheffield	a.m.little@sheffield.ac.uk
Katie Risdale	Research Assistant	University of Sheffield	k.ridsdale@sheffield.ac.uk
Noa Haynes	Research Assistant	University of Sheffield	noa.haynes@sheffield.ac.uk

---

Co-applicants

This project is funded by the National Institute for Health Research, Health Technology Assessment (NIHR HTA) Programme (Ref NIHR131861).

---

ORION trial sites

---

Publications 

Access the ORION trial protocol